Evidence map›Paper›PMID 31401015›Full record

ReviewTrends in endocrinology and metabolism: TEM2019

Heterogeneity and Similarities in GLP-1 Receptor Agonist Cardiovascular Outcomes Trials.

Irene Caruso, Angelo Cignarelli, Francesco Giorgino

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Trends in endocrinology and metabolism: TEM, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06606821 (The Effects of Tirzepatide on Coronary Plaque Lipid Content and Myocardial Microvascular Function in Overweight and Obese People With Coronary Disease - The IDEAL-COR Study), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
6.1field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06606821 phase4recruitingstarted 2024, after this paper: background citation

The Effects of Tirzepatide on Coronary Plaque Lipid Content and Myocardial Microvascular Function in Overweight and Obese People With Coronary Disease - The IDEAL-COR Study

Ran2024Enrolled124Registered outcomes23Posted comparisons0ConditionsAtherosclerosis Cardiovascular Disease, Chronic Coronary Artery Disease, Coronary Artery Disease, Coronary Microvascular DysfunctionArmsPlacebo, Tirzepatide
PMID 30293770PMID 27295427PMID 30473097PMID 27633186PMID 35658024PMID 34170647PMID 23644090PMID 31189511PMID 31378814PMID 31422062PMID 31448673PMID 32052833other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 59 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Irene CarusoDepartment of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
Angelo CignarelliDepartment of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy.
Francesco GiorginoDepartment of Emergency and Organ Transplantation, Section of Internal Medicine, Endocrinology, Andrology and Metabolic Diseases, University of Bari Aldo Moro, Bari, Italy. Electronic address: francesco.giorgino@uniba.it.
University of Bari Aldo Moro · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The latest recommendations from the American Diabetes Association and the European Association for the Study of Diabetes prioritize the use of drugs with proven cardiovascular (CV) benefit in patients with established CV disease. Especially among the glucagon-like peptide (GLP)-1 receptor agonists (GLP-1RA) class, results of cardiovascular outcomes trials (CVOT) have been heterogeneous. Baseline characteristics of the population, study design, drugs in the control arm, modifications of CV risk factors, including glycemic control, reduction of hypoglycemia, and the GLP-1RA direct effects on CV cells and tissues, were considered. Ultimately, the time of exposure to the GLP-1RA appears to be the factor most prominently explaining trial heterogeneity. Thus, the CV benefit should be regarded as a class effect of GLP-1RA, as largely similar results are seen for drugs sharing a common mechanism of action.

Indexed as

Glucagon-Like Peptide-1 Receptor AgonistsAnimalsCardiovascular DiseasesCardiovascular SystemGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHumansHypoglycemiaGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor Agonistscardiovascular diseasecardiovascular outcomes trialsGLP-1 receptor agonistglycemic controlhypoglycemiamajor adverse cardiovascular events

Identifiers

PMID31401015
OpenAlexW2964603908

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.